Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02622581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Study acronym: CRISP
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 11 months later Sep 2026 → Sep 2030
See other at-risk trials from AIO-Studien-gGmbH

Record History

  1. Primary completion pushed from Sep 2026 to Sep 2030 Enrollment increased: 12400 → 14500 participants · Completion pushed from Dec 2027 to Sep 2031 · Trial arms changed: 5 → 6 · 3 more Show 6 more changesShow less
    • Enrollment increased: 12400 → 14500 participants
    • Completion pushed from Dec 2027 to Sep 2031
    • Trial arms changed: 5 → 6
    • Eligibility criteria shortened, about 69 words
    • Collaborators: 17 to 19
    • Publications: details revised at 3 of 3 entries
  2. Re-verified, no change to tracked fieldsv15
  3. Collaborators: 15 to 17v14 See this version in full on ClinicalTrials.gov ↗
  4. Primary completion date: Sep 2023 to Sep 2026 Collaborators: 14 to 15v13 Show 1 more changeShow less
    • Collaborators: 14 to 15

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 7500 to 12400 Eligibility criteria expanded, about 46 words · Collaborators: 13 to 14v12 Show 2 more changesShow less
    • Eligibility criteria expanded, about 46 words
    • Collaborators: 13 to 14

    See this version in full on ClinicalTrials.gov ↗

Show 10 earlier versionsHide 10 earlier versions
  1. Completion date: Dec 2025 to Dec 2027 Collaborators: 12 to 13v11 Show 1 more changeShow less
    • Collaborators: 12 to 13

    See this version in full on ClinicalTrials.gov ↗

  2. Collaborators: 11 to 12v10 See this version in full on ClinicalTrials.gov ↗
  3. Enrollment target: 5000 to 7500 Primary completion date: Sep 2021 to Sep 2023 · Completion date: Dec 2022 to Dec 2025 · Eligibility criteria expanded, about 123 words · 3 morev9 Show 6 more changesShow less
    • Primary completion date: Sep 2021 to Sep 2023
    • Completion date: Dec 2022 to Dec 2025
    • Eligibility criteria expanded, about 123 words
    • Study description expanded, about 8 words
    • Study title revised
    • Study arms: 3 to 5

    See this version in full on ClinicalTrials.gov ↗

  4. Collaborators: 10 to 11v8 See this version in full on ClinicalTrials.gov ↗
  5. Collaborators: 9 to 10v7 See this version in full on ClinicalTrials.gov ↗
  6. Collaborators: 8 to 9v6 See this version in full on ClinicalTrials.gov ↗
  7. Re-verified, no change to tracked fieldsv5
  8. Collaborators: 7 to 8v4 See this version in full on ClinicalTrials.gov ↗
  9. Collaborators: 6 to 7v3 See this version in full on ClinicalTrials.gov ↗
  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Trial Details
NCT Number NCT02622581
Lead Sponsor AIO-Studien-gGmbH
Collaborators: AstraZeneca, Celgene Corporation, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, iOMEDICO AG, Eli Lilly and Company, Roche Pharma AG, Takeda, Amgen, Janssen-Cilag G.m.b.H, GlaxoSmithKline, Regeneron Pharmaceuticals, Astellas Pharma Global Development, Inc., Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Daiichi Sankyo Deutschland GmbH, Gilead Sciences
Conditions Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Enrollment 14,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov